Company Overview

Update
Status:
Acquired by Cubist Pharmaceuticals
Founded:
2004
Headquarters:
San Diego, CA
IPO:
Went Public on Jul 30, 2013
Stock:
NASDAQ:TSRX
Categories:
Biotechnology

Trius Therapeutics is focused on the development of innovative antibiotics for life-threatening infections.

Description

Update

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections.

We have successfully completed two Phase 3 clinical trials for Tedizolid Phosphate (TR-701), formerly torezolid phosphate, in ABSSSI. Tedizolid is an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). With the continuous increase in bacterial resistance to currently marketed drugs, serious infections are becoming more difficult, if not impossible to treat, and this has led to a clear need for novel therapeutics to treat multi-drug resistant bacterial infections.

Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory... See More

Current Team (4)

Update

Board Members and Advisors (2)

Update

Funding Rounds (2) - $49.30M

Update

Offices/Locations (1)

Update
  • Office

    6310 Nancy Ridge Drive

    Suite 105

    San Diego, CA 92121

    USA

Images (1)

Update
  • 09933ae296c398e2033f4a6102f4fbcc